The ducks are certainly lined up here...Looking back we were due...

The ducks are certainly lined up here...

Looking back we were due to expect first commercial sales from PromarkerD in late 2017 but sadly for us a few unexpected speed humps have landed us here in 2019 coming into Q2 and yet to see receipts hit the books.

All is not lost though, we all know what's coming - a nice contract to expedite availability of the test to physicians as soon as possible. We saw what happened to the SP from the November announcement when the immunoassay kit was released. When the PHDx sales agreement got killed, naturally SP took a hit.. but this is were everyone get's a second chance to get in and take this opportunity.

It would be inconceivable that Richard would terminate the PHDx agreement if not already confident in securing an alternative partner that could deliver what his looking for - rapid deployment of the test kit into pathology laboratories. This can't be far from the horizon, tomorrow? next week? next month? time will tell. Time will also tell that the SP was high 40's on the anticipation of imminent commercial sales from PromarkerD back in November, I think we are going to smash through 50c once this new deal is announced.

We have the Dominican Republic and Mexico, Patia Biopharma sales to look forward too as well.
Biopharma was signed back in June 2018 so surely those sales will be trickling though anytime now?
Keep in mind, Patia Spain is also on the horizion - signed back in Oct 2018.

Japan, China, India, Australia - all in the pipeline.
Once this is being used in the U.S. it's easy sailing from there.

If that isn't enough to get you excited, the Endometriosis and Giardia Promarker studies are now edging closer to clinical trials as the POC stage is usually 3-6months. So we could see bombshells dropped over the next couple of months regarding these two studies (hoping for a positive outcome).

And let's not forget our future potential with Dimerix and their DMX-200 therapy (Which I also hold) - clinical trail outcome expected late this year, with Dimerix having the ability to license PromarkerD as a companion diagnostic test.

Here's what else I like, for J&J (Janssen) to partner with PIQ to utilize and test PromarkerD in predicting heart disease and declining kidney function, is a significant testimony to the underlying PromarkerD technology and it's credibility.
That's a $370 billion dollar company taking notice of tiny little $20M Proteomics International.

The books look healthy too!
$3M on hand with $350-500k coming in every quarter from the analytics division, I think we are looking pretty healthy with enough juice to keep running for another year. If PromarkerD sales aren't flowing through by then... well then I will be speechless and very much questioning Richard as a MD...

Anyhow just some late night thoughts, the buy side has weakened a little bit so thought it was time for a cheeky 'upramp' post

Oh I nearly forgot, we still have Atturos partnership for OCProDx (Prostate Cancer Progression Detection), though things have been very quiet - I have been periodically checking google for any news and updates from the Atturos group but they have not made any announcements since April 2018. Still another card up our sleeves..